Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Milrinone on Cardiac Performance in Patients Undergoing Off-pump Coronary Artery Bypass Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patient agree and provide written informed consent.
- patient undergoing elective coronary artery bypass graft surgery
- preoperative LV EF>50% (TTE)
Exclusion Criteria:
- preoperative cardiac dysrhythmia
- preoperative IABP
- use of other inotropic agents
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
TMAD
Tissue motion annular displacement (TMAD) of tricuspid valve annulus transesophageal echocardiography
|
giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75
mcg/kg/min IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
TMAD of ticuspid annulus during early relaxation
Time Frame: 15 mini after milrinone administration
|
15 mini after milrinone administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
global longitudinal strain of the right ventricle
Time Frame: 15 mini after milrinone administration
|
15 mini after milrinone administration
|
|
left ventricular ejection fraction
Time Frame: 15 min after milline administration
|
15 min after milline administration
|
|
global longitudinal strain of the left ventricle
Time Frame: 15 min after milline administration
|
15 min after milline administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Cardiotonic Agents
- Phosphodiesterase Inhibitors
- Phosphodiesterase 3 Inhibitors
- Milrinone
Other Study ID Numbers
Other Study ID Numbers
- KUH0000000123
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.